Browsing Tag
JCR Pharmaceuticals
3 posts
JCR Pharmaceuticals completes global Phase III enrollment for JR-141 targeting Hunter syndrome’s neurological symptoms
JCR Pharmaceuticals completes global Phase III enrollment for JR-141, targeting Hunter syndrome CNS symptoms with its BBB-penetrating enzyme therapy.
JR-446 developed by JCR Pharmaceuticals secures orphan drug designation from the European Commission for MPS IIIB
The European Commission has granted orphan drug status to JR-446 for MPS IIIB, supporting JCR Pharmaceuticals’ global rare disease expansion.
JCR Pharmaceuticals and Modalis Therapeutics enter next phase in gene therapy research
JCR Pharmaceuticals Co., Ltd. (TSE:4552) and Modalis Therapeutics Corporation (TSE:4883) have announced a pivotal advancement in their joint…